Susceptibility of adult rats to lead-induced changes in NMDA receptor complex function

Neurotoxicology and Teratology

Volumn 19, Issue 6, 1997, Pages 517-530

  Cory Slechta, D A ^a   Flaugher, C L ^a   Evans, S B ^a   Pokora, M J ^a   Greenamyre, J T ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

CGP 39653; Development; Drug discrimination; Lead; MK 801; NMDA receptor complex

Indexed keywords

2 AMINO 4 PHOSPHONOMETHYL 3 HEPTENOIC ACID; DIZOCILPINE; LEAD ACETATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DISCRIMINATION; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY;

2-AMINO-5-PHOSPHONOVALERATE; ANIMALS; AUTORADIOGRAPHY; BRAIN; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; LEAD; LEAD POISONING; MALE; RATS; RECEPTORS, N-METHYL-D-ASPARTATE;

ANIMALIA;

EID: 0030726083     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0892-0362(97)00047-0     Document Type: Article

References (57)

1. Alkondon M., Costa A. C. S., Radhakrishnan V., Aronstam R. S., Albuquerque E. X. Selective blockade of NMDA-activated channel currents may be implicated in learning deficits caused by lead. FEBS. 261:1990;124-130.
2. Altmann L., Sveinsson K., Wiegand H. Long term potentiation in rat hippocampal slices is impaired following acute lead perfusion. Neurosc. Lett. 128:1991;109-112.
3. Araki S., Yokoyama K., Aono H., Murata K. Psychological performance in relation to central and peripheral nerve conduction in workers exposed to lead, zinc and copper. Am. J. Ind. Med. 9:1986;535-542.
4. 1 receptors. An autoradiographic study Drug Dev. Res. 29:1993;40-47.
5. 3H]MK-801 binding to well-washed rat brain membranes following cessation of chronic phencyclidine treatment. Pharmacol. Biochem. Behav. 51:1995;435-438.
6. Bushnell P. J., Bowman R. E. Reversal learning deficits in young monkeys exposed to lead. Pharmacol. Biochem. Behav. 10:1979;733-742.
7. Cohn J., Cory-Slechta D. A. Subsensitivity of lead-exposed rats to the accuracy-impairing and rate-altering effects of MK-801 on a multiple schedule of repeated learning and performance. Brain Res. 600:1993;208-218.
8. Cohn J., Cory-Slechta D. A. Lead exposure potentiates the effects of N-methyl-d-aspartate on repeated learning. Neurotoxicol. Teratol. 16:1994;455-466.
9. Cohn J., Cox C., Cory-Slechta D. A. The effects of lead exposure on learning in a multiple schedule of repeated acquisition and performance. Neurotoxicology. 14:1993;329-346.
10. Cory-Slechta D. A. Lead exposure during advanced age. Alterations in kinetics and biochemical effects Toxicol. Appl. Pharmacol. 104:1990;67-78.
11. Cory-Slechta D. A. Relationships between lead-induced learning impairments and changes in dopaminergic, cholinergic and glutamatergic neurotransmitter system functions. Annu. Rev. Pharmacol. Toxicol. 35:1995;391-415.
12. Cory-Slechta D. A. MK-801 subsensitivity following postweaning lead exposure. Neurotoxicology. 6:1995;85-96.
13. Cory-Slechta D. A. Postnatal lead exposure and MK-801 sensitivity. Neurotoxicol. 18:1997;209-220.
14. Cory-Slechta D. A., Garcia-Osuna M., Greenamyre T. J. Lead-induced changes in NMDA receptor binding. Correlations with learning accuracy and with sensitivity to learning impairments caused by MK-801 and NMDA administration Behav. Brain Res. 85:1997;161-174.
15. 1 agonist SKF82958 J. Neurochem. 68:1997;2012-2023.
16. Cory-Slechta D. A., Pokora M. J. Behavioral manifestations of prolonged lead exposure initiated at different stages of the life cycle. I Schedule-controlled responding. Neurotoxicology. 12:1991;745-760.
17. Cory-Slechta D. A., Pokora M. J., Fox R. A. V., O'Mara D. J. Lead-induced changes in dopamine D1 sensitivity. Modulation by drug discrimination training Neurotoxicology. 17:1996;445-458.
18. Cory-Slechta D. A., Pokora M. J., Johnson J. L. Postweaning lead exposure enhances the stimulus properties of N-methyl-d-aspartate. Possible dopaminergic involvement? Neurotoxicology. 17:1996;509-522.
19. Cory-Slechta D. A., Pokora M. J., Widzowski D. V. Postnatal lead exposure induces a supersensitivity to the stimulus properties of a D2-D3 agonist. Brain Res. 598:1992;162-172.
20. Cory-Slechta D. A., Weiss B., Cox C. Performance and exposure indices of rats exposed to low concentrations of lead. Toxicol. Appl. Pharmacol. 78:1985;291-299.
21. Cory-Slechta D. A., Weiss B., Cox C. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetracetate chelation therapy. J. Pharmacol. Exp. Ther. 243:1987;804-813.
22. Cory-Slechta D. A., Widzowski D. V. Low level lead exposure increases sensitivity to the stimulus properties of dopamine D1 and D2 agonists. Brain Res. 553:1991;65-74.
23. Cotman C. W., Bridges R. J., Taube J. S., Clark A. S., Geddes W., Monaghan D. T. The role of the NMDA receptor in central nervous system plasticity and pathology. J. NIH Res. 1:1989;65-74.
24. Dall'olio R., Gandolfi O., Montanaro N. Effect of chronic treatment with dizocilpine (MK-801) on the behavioral response to dopamine receptor agonists in the rat. Psychopharmacology (Berlin). 107:1992;591-594.
25. Davis J. M., Svendsgaard D. J. U-shaped dose-response curve-shaped dose-response curves. Their occurrence and implications for risk assessment J. Toxicol. Environ. Health. 30:1990;71-83.
26. Gandolfi O., Dall'olio R. Chronic treatment with MK-801 decreases D2 dopamine receptor function in rat striatum. Pharmacol. Biochem. Behav. 44:1993;683-687.
27. 3H]MK-801 binding in NMDA receptor-gated ionophore. In vitro and in vivo studies Neurosci. Lett. 148:1992;27-30.
28. Guilarte T. R. Miceli, R. C.; Jett, D. A. Biochemical evidence of an interaction of lead at the zinc allosteric sites of the NMDA receptor complex: Effects of neuronal development. Neurotoxicology 16:1995;63-72.
29. Hanninen H., Mantere P., Hernberg S., Seppalainen A. M., Kock B. Subjective symptoms in low-level exposure to lead. Neurotoxicology. 1:1979;333-347.
30. Hogstedt C., Hane M., Agrell A., Bodin L. Neuropsychological test results and symptoms among workers with well-defined long-term exposure to lead. Br. J. Ind. Med. 40:1983;99-105.
31. 3H]CGP-39653 to NMDA receptors in the autoradiographic assay. J. Neurosci. Methods. 46:1993;133-138.
32. Jett D. A., Guilarte T. R. Developmental lead exposure alters N-Methyl-d-aspartate and muscarinic cholinergic receptors in the rat hippocampus. An autoradiogiaphic study Neurotoxicology. 16:1995;7-18.
33. Lasley S. M., Polan-Curtain J., Armstrong D. L. Chronic exposure to environmental levels of lead impairs in vivo induction of long term potentiation in rat hippocampal dentate. Brain Res. 614:1993;347-351.
34. Lilienthal H., Winneke G., Brockhaus A., Molik B. Pre- and postnatal lead exposure in monkeys. Effects on activity and learning set formation Neurotoxicol. Teratol. 8:1986;265-272.
35. McCoy, L.; Richfield, E. K.; Cory-Slechta, D. A.: Regional changes in AMPA binding in response to chronic low-level lead exposure: Reversal by chronic dopamine agonist treatment. J. Neurochem. (in press).
36. Micheletti G., Lannes B., Haby C., Borrelli E., Kempf E., Warter J-M., Zwiller J. Chronic administration of NMDA antagonists induces D2 receptor synthesis in rat striatum. Mol. Brain Res. 14:1992;363-368.
37. Monyer H., Burnashev N., Laurie D. J., Sakmann B., Seeburg P. H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 12:1994;529-540.
38. Parkinson D. K., Ryan C., Bromet E. J., Connell M. M. A psychiatric epidemiologic study of occupational lead exposure. Am. J. Epidemiol. 123:1986;261-269.
39. Pokora M. J., Cory-Slechta D. A., Richfield E. K. Time-course of lead (Pb)-induced changes in D1, D2 and DAUC binding sites in dorsal striatum and nucleus accumbens during chronic postweaning exposure. Soc. Neurosci. Abstr. 21:1995;94.
40. Pokora M. J., Richfield E. K., Cory-Slechta D. A. Preferential vulnerability of nucleus accumbens dopamine binding sites to low-level lead exposure. Time course of effects and interactions with chronic dopamine agonist treatments J. Neurochem. 67:1996;1540-1550.
41. Quirion R., Bayorh M. A., Zerbe R. L., Pert C. B. Chronic phencyclidine treatment decreases phencyclidine and dopamine receptors in rat brain. Pharmacol. Biochem. Behav. 17:1982;699-702.
42. Rice D. C. Chronic low-lead exposure from birth produces deficits in discrimination reversal in monkeys. Toxicol. Appl. Pharmacol. 75:1985;201-210.
43. Rice D. C., Gilbert S. G. Effects of developmental exposure to methyl-mercury on spatial and temporal visual function in monkeys. Toxicol. Appl. Pharmacol. 102:1990;151-163.
44. Richfield E. K., McCoy L., Cory-Slechta D. A. Regional effects of chronic lead exposure on MK-801 and AMPA binding in rat brain. Soc. Neurosci. Abstr. 22:1996;1534.
45. Riva M. A., Tascedda F., Molteni R., Racagni G. Regulation of NMDA receptor subunit mRNA expression in the rat brain during postnatal development. Mol. Brain Res. 25:1994;209-216.
46. 3H-MK-801 binding to NMDA-receptors in the brain of mice. Neurotoxicology. 16:1995;309-317.
47. Stewart J., Badiani A. Tolerance and sensitization to the behavioral effects of drugs. Behav. Pharmacol. 4:1993;289-312.
48. Stollery B. T., Banks H. A., Broadbent D. E., Lee W. R. Cognitive functioning in lead workers. Br. J. Ind. Med. 48:1989;698-707.
49. Stollery B. T., Broadbent D. E., Banks H. A., Lee W. R. Short term prospective study of cognitive functioning in lead workers. Br. J. Ind. Med. 48:1991;739-749.
50. Ujihara H., Albuquerque E. X. Developmental change of the inhibition by lead of NMDA-activated currents in cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 263:1992;868-875.
51. Uteshev V., Busselberg D., Hass H. L. Pb2+ modulates the NMDA-receptor-complex channel. Naunyn Schmiedeburgs Arch. Pharmacol. 347:1993;209-213.
52. Wenzel A., Villa M., Mohler H., Benke D. Developmental and regional expression of NMDA receptor subtypes containing the NR2D subunit in rat brain. J. Neurochem. 66:1996;1240-1248.
53. Widzowski D. V., Cory-Slechta D. A. Homogeneity of regional brain lead concentrations. Neurotoxicology. 15:1994;295-308.
54. Wolf M. E., White F. J., Hu X-T. Behavioral sensitization to MK-801 (dizocilpine). Neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system Behav. Pharmacol. 4:1993;429-442.
55. World Health Organization. Inorganic lead. Environmental Health Criteria 165. Geneva: World Health Organization; 1995.
56. Yokoyama K., Araki S., Aono H. Reversibility of psychological performance in subclinical lead absorption. Neurotoxicology. 9:1988;405-410.
57. Zhong J., Carrozza D. P., Williams K., Pritchett D. B., Molinoff P. B. Expression of mRNAs encoding subunits of the NMDA receptor in the developing brain. J. Neurochem. 64:1995;531-539.